Gaithersburg, MD, United States of America

Manuel Baca

USPTO Granted Patents = 33 (Patent Applications = 11)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 3.8

ph-index = 9

Forward Citations = 840(Granted Patents)

Location History:

Foster City, CA (US) (2005 - 2007)
Black Rock, AU (2008)
Ivanhoe, AU (2006 - 2012)
Viewbank, AU (2007 - 2014)
Gaithersburg, MD (US) (2010 - 2024)

Company Filing History:

Zenyth Operations Pty. Ltd.

patents

5. 3 out of 80

The Walter and Eliza Hall Institute of Medical Research

The University of Queensland

where one patent can have more than one assignee

Years Active: 2005-2024

Loading Chart...

33 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12071484 - Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein (2024-08-27),

2. 11555062 - Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer (2023-01-17),

3. 11098289 - Uricase sequences and methods of treatment (2021-08-24),

4. 10975155 - CD40L-Fc fusion polypeptides and methods of use thereof (2021-04-13),

5. 10883087 - Uricase sequences and methods of treatment (2021-01-05),

6. 10106617 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2018-10-23),

7. 10000553 - CD40L-specific TN3-derived scaffolds and methods of use thereof (2018-06-19),

8. 9777062 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2017-10-03),

9. 9371388 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2016-06-21),

10. 9212231 - TRAIL R2-specific multimeric scaffolds (2015-12-15),

11. 9193793 - Antibodies against G-CSFR and uses thereof (2015-11-24),

12. 9176129 - Protein scaffolds (2015-11-03),

13. 8822644 - Method of treating cancer comprising a VEGF-B antagonist (2014-09-02),

14. 8633297 - Protein scaffolds (2014-01-21),

15. 8613925 - Anti-IL-13Rα1 antibodies and their uses thereof (2013-12-24),

Title: The Inventor Spotlight: Manuel Baca

Introduction:

Manuel Baca, a prolific inventor based in Gaithersburg, MD, has made significant contributions to the field of biomedical research with an impressive portfolio of 32 patents. His groundbreaking work has focused on novel methods of administering compositions for targeted therapies, as well as innovative sequences for the treatment of hyperuricemia.

Latest Patents:

Manuel Baca's latest patents showcase his ingenuity and commitment to advancing medical solutions. One notable invention is the development of Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L, with engineered variants designed to enhance affinity for the target. These engineered scaffolds hold promise for therapeutic applications in treating autoimmune diseases such as SLE. Additionally, his work on uricase sequences has led to improved treatments for patients suffering from hyperuricemia.

Career Highlights:

Throughout his career, Manuel Baca has made significant contributions to cutting-edge research at renowned companies such as CSL Limited and Genentech, Inc. His expertise and innovative thinking have been instrumental in advancing the boundaries of biomedical science and bringing transformative solutions to the healthcare industry.

Collaborations:

Manuel Baca has collaborated closely with esteemed colleagues such as Andrew Donald Nash and Louis Jerry Fabri, who have played pivotal roles in shaping the success of his research endeavors. Together, they have fostered a culture of collaboration and innovation, leading to groundbreaking discoveries and advancements in the field of biomedicine.

Conclusion:

In conclusion, Manuel Baca's dedication to pushing the boundaries of innovation in biomedical research is truly commendable. His remarkable portfolio of patents stands as a testament to his pioneering spirit and unwavering commitment to improving patient outcomes through cutting-edge therapies. Manuel Baca's work continues to inspire and pave the way for future advancements in the field of medical science.

This text is generated by artificial intelligence and may not be accurate.